IMMP Jumps 1688.5%, IOVA Up 37.2% on EPS Estimate Upgrades
Immutep (IMMP) surged 1688.5% to $4.65 after our EPS revision screener flagged it on September 27, while Iovance Biotherapeutics (IOVA) climbed 37.2% to $14.82 following a raised FY2026 revenue outlook of $410–$420 million on September 29. Cardinal Infrastructure (CDNL) gained 9.2%, Camtek (CAMT) rose 8.9%, and LuxExperience (LUXE) advanced 8.0% as analysts continued revising next-year EPS estimates upward across healthcare, industrials, technology, and consumer sectors.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| IMMP | Healthcare | 2026-09-27 | N/A | +1688.5% |
| IOVA | Healthcare | 2026-09-24 | N/A | +37.2% |
| CDNL | Industrials | 2026-09-25 | N/A | +9.2% |
| CAMT | Technology | 2026-09-28 | N/A | +8.9% |
| LUXE | Consumer Cyclical | 2026-09-24 | +162.6pp | +8.0% |
Why did IMMP stock jump in October 2026?
IMMP jumped 1,688.5% (from $0.26 to $4.65) after analysts raised its next-year EPS growth estimate to 25.5% on September 27.
The penny stock's explosive move reflects the outsized impact of earnings estimate revisions on low-priced shares, where even modest upward adjustments can trigger exponential gains. No company-specific news was identified during the observation window, suggesting the rally was driven primarily by the EPS revision signal itself and increased investor attention on Immutep's immunotherapy pipeline in the healthcare sector.
IMMP EPS revision history → · Screener snapshot from 2026-09-27 →
FAQ: IMMP
Why did IMMP stock jump 1688.5%?
IMMP surged from $0.26 to $4.65 after our EPS revision screener detected an upward revision in next-year growth estimates to 25.5% on September 27, with no company-specific news released during the period.
Is IMMP a buy after its massive rally?
Immutep Limited is a clinical-stage immunotherapy company with no revenue and no earnings-related news in the window; the 25.5% next-year EPS growth estimate is forward-looking and any investment decision should account for the stock's extreme volatility. Consult a financial advisor before trading.
What is IMMP's EPS growth estimate?
Immutep's next-year EPS growth estimate is 25.5% as of the September 27, 2026 detection date, according to our EPS revision screener.
Why did IOVA stock jump in October 2026?
IOVA jumped 37.2% (from $10.80 to $14.82) after analysts signaled a 52.0% next-year EPS growth estimate and the company raised FY2026 revenue guidance to $410–$420 million on September 29.
The revised midpoint of $415 million cleared consensus of $402.8 million, reflecting nearly 60% annual revenue growth driven by record Q2 product revenue of $99.3 million, including $89.5 million from Amtagvi. Management cited increasing patient demand, a manufacturing schedule with strong visibility into Q3 and Q4, and an expanding network of authorized treatment centers approaching 100 locations. The stock hit over two-year highs as the raised outlook confirmed the EPS revision signal the screener caught on September 24.
IOVA EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: IOVA
Why did IOVA stock jump 37.2%?
Iovance Biotherapeutics surged from $10.80 to $14.82 after raising FY2026 revenue guidance to $410–$420 million on September 29, clearing consensus of $402.8 million and signaling nearly 60% annual growth driven by Amtagvi demand.
What caused Iovance Biotherapeutics' surge?
The surge was driven by a $55 million midpoint guidance increase, record Q2 product revenue of $99.3 million, and management's confidence in Q3/Q4 visibility, which validated the 52.0% next-year EPS growth estimate our screener detected on September 24.
Is IOVA a buy after the rally?
Iovance is a commercial-stage biotech with $410–$420 million in expected FY2026 revenue and expanding treatment centers, but the stock already rallied 37.2% to over two-year highs; investors should weigh the raised outlook against valuation and pipeline execution risks.
Why did CDNL stock jump in October 2026?
CDNL climbed 9.2% (from $28.02 to $30.60) after analysts revised its next-year EPS growth estimate to 29.6% on September 25.
The infrastructure company's gain reflects broader strength in the industrials sector, where backlog visibility and pricing power are supporting upward earnings revisions. No company-specific news was identified in the window, indicating the move was primarily driven by the earnings estimate revision and sector tailwinds.
CDNL EPS revision history → · Screener snapshot from 2026-09-25 →
FAQ: CDNL
Why did CDNL stock rise 9.2%?
Cardinal Infrastructure Group gained from $28.02 to $30.60 after our EPS revision screener detected a 29.6% next-year EPS growth estimate on September 25, with no company-specific news released during the period.
What is CDNL's EPS growth estimate?
Cardinal Infrastructure Group's next-year EPS growth estimate is 29.6% as of the September 25, 2026 detection date.
Is CDNL a buy after its recent gain?
CDNL's 9.2% move was driven by an EPS estimate revision to 29.6% next-year growth with no earnings-related news; investors should evaluate the infrastructure sector's backlog trends and the company's execution before making a decision.
Why did CAMT stock jump in October 2026?
CAMT rose 8.9% (from $142.61 to $155.25) after analysts lifted its next-year EPS growth estimate to 35.6% on September 28.
The semiconductor inspection equipment maker benefited from continued capital spending in advanced packaging and AI-driven chip demand, which supports upward earnings revisions across the technology sector. No company-specific news was found, suggesting the price move was a direct response to the improved earnings outlook.
CAMT EPS revision history → · Screener snapshot from 2026-09-28 →
FAQ: CAMT
Why did CAMT stock gain 8.9%?
Camtek Ltd rose from $142.61 to $155.25 after our EPS revision screener detected a 35.6% next-year EPS growth estimate on September 28, with no company-specific news released during the window.
What is CAMT's EPS growth estimate?
Camtek's next-year EPS growth estimate is 35.6% as of the September 28, 2026 detection date, according to our EPS revision screener.
Is CAMT a buy after its recent rally?
Camtek's 8.9% gain was driven by a 35.6% next-year EPS growth estimate and broader semiconductor capital spending trends; investors should consider the company's exposure to advanced packaging and AI chip demand before investing.
Why did LUXE stock jump in October 2026?
LUXE advanced 8.0% (from $9.18 to $9.91) after analysts raised its next-year EPS growth estimate to 2,281.3%, a 162.6 percentage point upward revision, on September 24.
The extreme revision reflects a low base effect in the consumer cyclical sector, where post-pandemic demand normalization is driving outsized percentage growth in earnings estimates. No company-specific news was identified, indicating the move was primarily driven by the dramatic EPS estimate revision.
LUXE EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: LUXE
Why did LUXE stock rise 8.0%?
LuxExperience B.V ADR gained from $9.18 to $9.91 after our EPS revision screener detected a 2,281.3% next-year EPS growth estimate on September 24, a 162.6 percentage point upward revision with no company-specific news.
What is LUXE's EPS growth estimate?
LuxExperience's next-year EPS growth estimate is 2,281.3% as of the September 24, 2026 detection date, up from a prior estimate of 2,118.8%.
Is LUXE a buy after its recent gain?
LUXE's 8.0% move was driven by an extreme EPS estimate revision to 2,281.3% next-year growth, but the percentage reflects a low base; investors should evaluate the underlying consumer cyclical trends and the company's actual earnings trajectory.
Today's top performers highlight the market's continued willingness to reward upward EPS estimate revisions, particularly in healthcare and technology where Iovance's raised guidance and Camtek's semiconductor exposure reflect accelerating fundamental momentum. The outsized gains in low-priced names like IMMP and LUXE underscore how estimate revisions can trigger disproportionate price moves when combined with sector tailwinds.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →